Cyclopharm Ltd Market Cap ($40.48 Million)
Market Cap & Net Worth: Cyclopharm Ltd (CYC)
Cyclopharm Ltd market cap. Cyclopharm Ltd (AU:CYC) has a market capitalization of $40.48 Million (AU$57.21 Million) as of November 8, 2026. Listed on the AU stock exchange, this Australia-based company holds position #22425 globally and #793 in its home market, demonstrating a 18.18% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cyclopharm Ltd's stock price AU$0.46 by its total outstanding shares 125734145 (125.73 Million). Also see CYC cash generation efficiency for how efficiently the company converts equity into cash flow.
Cyclopharm Ltd Market Cap History (2015–2026)
Cyclopharm Ltd market cap history from 2015 to 2026. Data shows growth from $42.71 Million to $40.48 Million (0.43% CAGR). Check Cyclopharm Ltd stock quote for real-time trading data and today's change.
Cyclopharm Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cyclopharm Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore CYC net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.70x
Cyclopharm Ltd's market cap is 2.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $75.78 Million | $14.39 Million | $891.37K | 5.27x | 85.02x |
| 2017 | $80.84 Million | $13.19 Million | -$1.52 Million | 6.13x | N/A |
| 2018 | $94.96 Million | $13.40 Million | -$35.46K | 7.08x | N/A |
| 2019 | $102.25 Million | $14.08 Million | -$2.91 Million | 7.26x | N/A |
| 2020 | $218.69 Million | $14.68 Million | -$6.04 Million | 14.90x | N/A |
| 2021 | $144.18 Million | $17.70 Million | -$5.04 Million | 8.14x | N/A |
| 2022 | $103.53 Million | $23.22 Million | -$6.61 Million | 4.46x | N/A |
| 2023 | $171.26 Million | $26.34 Million | -$4.70 Million | 6.50x | N/A |
| 2024 | $141.01 Million | $27.57 Million | -$13.20 Million | 5.11x | N/A |
| 2025 | $87.19 Million | $32.33 Million | -$17.22 Million | 2.70x | N/A |
Competitor Companies of CYC by Market Capitalization
Companies near Cyclopharm Ltd in the global market cap rankings as of November 8, 2026. Also see CYC total asset value for a full breakdown of the balance sheet.
Key companies related to Cyclopharm Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #109 globally with a market cap of $191.15 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #188 globally with a market cap of $124.99 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #222 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #233 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #109 | Abbott Laboratories | NYSE:ABT | $191.15 Billion | $109.93 |
| #188 | Stryker Corporation | NYSE:SYK | $124.99 Billion | $325.87 |
| #222 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $101.80 |
| #233 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of Cyclopharm Ltd (2015–2026)
Market capitalization of Cyclopharm Ltd from 2015 to today. Between 2015 and today, Cyclopharm Ltd's market cap moved from $42.71 Million to $ 40.48 Million, with a yearly change of 0.43%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$40.48 Million | -53.57% |
| 2025 | AU$87.19 Million | -38.17% |
| 2024 | AU$141.01 Million | -17.66% |
| 2023 | AU$171.26 Million | +65.42% |
| 2022 | AU$103.53 Million | -28.19% |
| 2021 | AU$144.18 Million | -34.07% |
| 2020 | AU$218.69 Million | +113.89% |
| 2019 | AU$102.25 Million | +7.67% |
| 2018 | AU$94.96 Million | +17.46% |
| 2017 | AU$80.84 Million | +6.68% |
| 2016 | AU$75.78 Million | +77.42% |
| 2015 | AU$42.71 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of Cyclopharm Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $40.48 Million USD |
| MoneyControl | $40.48 Million USD |
| MarketWatch | $40.48 Million USD |
| marketcap.company | $40.48 Million USD |
| Reuters | $40.48 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cyclopharm Ltd
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribu… Read more